Arch Biopartners Inc V.ARCH

Way, Way too Early for a Buyout, But!!!!

[SrPlata]

Think about this, If big Pharma is looking to buyout Arch. It would have to be an extremley generous offer to current market price 5X, 6x,7x, 10x?????Who knows. But Arch insiders won't sell us out cheaply like some management would, IE If they own less than 10% and they are offered Golden Parachutes with generous  severance packages they will sell out shareholders for their own benefit. Arch Management and insiders own roughly 59% Plus another 6% Friends and Family. In addition Mgt knows what they have on their hands and how valuable the platform technology is. Arch developed this Drug Platform over 10 years and own it outright unlike other Bio Tech companies that licence the formula from Universities or others. So no Royalties over hanging them. Basically Arch is in the drivers seat and will control their(our) destiny.

[2019champs]

It's going to come down to data when determining fair value for the drug / company. Everyone's speculating that data is good based on company going for peer review.. the question now is, how good is the data? In mice the survival rate was increased by 83% when administered with metablok. What's the efficacy in the human body? That's the real question and that will determine where